TNFR2: A Novel Target for Cancer Immunotherapy.

Vanamee, Éva S; Faustman, Denise L

Vanamee, Éva S; Faustman, Denise L.

Affiliation

Vanamee ÉS; Immunobiology Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA.
Faustman DL; Immunobiology Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. Electronic address: faustman@helix.mgh.harvard.edu.

Trends Mol Med ; 23(11): 1037-1046, 2017 11.

Article in En | MEDLINE | ID: mdl-29032004

Subject(s)

Neoplasms/immunology; Neoplasms/therapy; Receptors, Tumor Necrosis Factor, Type II/immunology; Animals; Humans; Immunotherapy/methods; NF-kappa B/immunology; Signal Transduction/immunology; T-Lymphocytes, Regulatory/immunology; Tumor Microenvironment/immunology

Key words

TNFR2 antagonism; cancer; checkpoint inhibitors; immunotherapy; oncogene; regulatory T cells; tumor microenvironment

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptors, Tumor Necrosis Factor, Type II / Neoplasms Limits: Animals / Humans Language: En Year: 2017 Type: Article

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptors, Tumor Necrosis Factor, Type II / Neoplasms Limits: Animals / Humans Language: En Year: 2017 Type: Article